Evidence map›Paper›PMID 41459858›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2025

Evaluation of Mismatch Repair (MMR) and Breast Cancer-1 (BRCA-1) Statuses in Epithelial Ovarian Cancer.

Richa Singh, Preeti Agarwal, Shuchi Agrawal, Eva Raman, Vandana Solanki, Puneet Prakash, Malti Kumari Maurya, Riddhi Jaiswal, Sameer Gupta

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Richa SinghDepartment of Pathology, King George's Medical University, Lucknow, UP, India.
Preeti AgarwalDepartment of Pathology, King George's Medical University, Lucknow, UP, India.ORCID 0000000181078501
Shuchi AgrawalDepartment of Obstetrics and Gynecology, King George's Medical University, Lucknow, UP, India.ORCID 0000-0002-1847-5472
Eva RamanDepartment of Obstetrics and Gynecology, King George's Medical University, Lucknow, UP, India.
Vandana SolankiDepartment of Obstetrics and Gynecology, King George's Medical University, Lucknow, UP, India.
Puneet PrakashDepartment of Surgical Oncology, King George's Medical University, Lucknow, UP, India.
Malti Kumari MauryaDepartment of Pathology, King George's Medical University, Lucknow, UP, India.
Riddhi JaiswalDepartment of Pathology, King George's Medical University, Lucknow, UP, India.
Sameer GuptaDepartment of Surgical Oncology, King George's Medical University, Lucknow, UP, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aims to evaluate the expression of BRCA1 and MMR proteins using immunohistochemistry (IHC) in epithelial ovarian cancers and to explore their clinicopathological correlations. METHODOLOGY: IHC was performed and interpreted for BRCA1, MLH1, MSH2, MSH6, and PMS2. The results were then compared with clinical and pathological variables.

resultsOver a period of 19 months, 508 specimens containing ovarian tissue were received, either as part of a hysterectomy or as isolated samples for various indications. Among these, 24.01% (122/508) showed invasive epithelial ovarian cancer. Of these, 49 resection specimens had sufficient tumor tissue for detailed immunohistochemistry (IHC) analysis and were included in the study. Among the evaluated cases, 51% (25/49) of invasive epithelial ovarian cancers exhibited deficient mismatch repair (dMMR). No significant correlation was observed between dMMR and pMMR with respect to grade, cellularity, and high-grade features. Patients with dMMR showed better survival, which may be due to improved response to chemotherapy in these cases. Total loss of BRCA1 was seen in 36.7% (18/49) of cases. BRCA1 loss was associated with poor predictive factors but had better prognosis. Loss of BRCA1 was associated with aggressive tumors but had better response to chemotherapy. Both MMR and BRCA1 were independent variables. The overall survival of our patient population with epithelial ovarian cancer was 86.8%.

conclusionA significant number of patients displayed dMMR and BRCA1 loss by IHC. These patients may benefit from targeted therapy, and IHC may serve as an acceptable technique for each evaluation.

Indexed as

Biomarkers, TumorBRCA1 ProteinDNA Mismatch RepairOvarian NeoplasmsAdultAgedAged, 80 and overCarcinoma, Ovarian EpithelialDNA-Binding ProteinsFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesMiddle AgedMismatch Repair Endonuclease PMS2MutL Protein Homolog 1Biomarkers, TumorBRCA1 ProteinBRCA1 protein, humanDNA-Binding ProteinsG-T mismatch-binding proteinMismatch Repair Endonuclease PMS2MLH1 protein, humanMSH2 protein, humanMutL Protein Homolog 1MutS Homolog 2 ProteinPMS2 protein, humanBRCA1Epithelial cancers of ovaryimmunohistochemistryMMROvarian cancers

Identifiers

PMID41459858
PMCPMC13242554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.